Age and Gender as Predictors of Benefit From Aminophylline Administration in Patients Undergoing Regadenoson Stress Myocardial Perfusion Imaging
| Autor: | Maria Octavia Rangel, Rami Doukky, Raysa Morales Demori |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Risk medicine.medical_specialty Adenosine A2 Receptor Agonists Placebo law.invention Sex Factors Double-Blind Method Randomized controlled trial law Internal medicine Clinical endpoint Humans Medicine Pharmacology (medical) Adverse effect Aged Pharmacology business.industry Age Factors Myocardial Perfusion Imaging Absolute risk reduction General Medicine Middle Aged Aminophylline Regadenoson Purinergic P1 Receptor Antagonists Tolerability Purines Cardiology Pyrazoles Administration Intravenous Female business medicine.drug |
| Zdroj: | American Journal of Therapeutics. 20:622-629 |
| ISSN: | 1075-2765 |
| Popis: | Regadenoson is a selective adenosine A2A-receptor agonist, used as a pharmacological stress agent for myocardial perfusion imaging. It is associated with frequent adverse effects (AEs), particularly among individuals younger than 65 years of age and women. Intravenous aminophylline administration following regadenoson, as described in the ASSUAGE trial, reduces the incidence of AE. In this substudy of the ASSUAGE trial, we compared the absolute and relative benefits of aminophylline administration versus placebo, between subgroups of age ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|